Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News AstraZeneca to discuss safety of MDD drug

AstraZeneca to discuss safety of MDD drug

26th February 2009

AstraZeneca will meet with a regulatory body to discuss the safety and efficacy of a drug proposed to treat major depressive disorder (MDD) and generalised anxiety disorder.

The medication, Seroquel XR, was approved for the acute and maintenance therapy for adults with schizophrenia in 2007 and then for depressive episodes associated with bipolar disorder in 2008.

It is designed to be taken once a day and has an extended release formulation of Seroquel.

The pharmaceutical company will meet with the Food and Drug Administration on April 8th 2009 to go through a review of the potential benefits and risks the treatment may cause to the conditions AstraZeneca now proposes to treat with it.

In related news, the firm announced earlier this week that a phase III clinical trial of Unit Dose Budesonide for the potential remedy of asthma in children did not achieve the desired results.

AstraZeneca researches, develops, manufactures and markets a range of prescription medicines.

It focuses on remedies for cardiovascular, gastrointestinal, respiratory and infectious diseases.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.